Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 plus pembrolizumab in liver metastases from colorectal or gastric/gastro-oesophageal junction cancer
2019-004624-38Phase 2Terminated
- Sponsor
- Highlight Therapeutics
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoplexed poly I:C and pembrolizumab in colorectal cancer (CRC), gastric cancer (GC) and esophagogastric junction cancer, sponsored by Highlight Therapeutics. Primary endpoint: Objective response rate. Started Feb 2020; status: terminated.
02
Drugs
nanoplexed poly I:Cpembrolizumab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2019-004624-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004624-38.